Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor

Sheng Y Ang, Dana S Hutchinson, Nitin Patil, Bronwyn A Evans, Ross A D Bathgate, Michelle L. Halls, Mohammed A. Hossain, Roger J Summers, Martina Kocan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background and Purpose: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. Experimental Approach: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen® proximity assays. Recruitment of Gαi/o proteins by RXFP4 receptors was determined by rescue of Pertussis toxin (PTX)-inhibited cAMP and ERK1/2 responses following transient transfection of PTX-insensitive Gαi/o C351I mutants. Cell proliferation was studied with bromodeoxyuridine. RXFP4 receptor interactions with β-arrestins, GPCR kinase 2 (GRK2), KRas and Rab5a was assessed with real-time BRET. Gene expression was investigated using real-time quantitative PCR. Insulin release was measured using HTRF and intracellular Ca2 + flux monitored in a Flexstation® using Fluo-4-AM. Key Results: INSL5 inhibited forskolin-stimulated cAMP accumulation and increased phosphorylation of ERK1/2, p38MAPK, Akt Ser473, Akt Thr308 and S6 ribosomal protein. cAMP and ERK1/2 responses were abolished by PTX and rescued by mGαoA, mGαoB and mGαi2 and to a lesser extent mGαi1 and mGαi3. RXFP4 receptors interacted with GRK2 and β-arrestins, moved towards Rab5a and away from KRas, indicating internalisation following receptor activation. INSL5 inhibited glucose-stimulated insulin secretion and Ca2 + mobilisation in MIN6 insulinoma cells and forskolin-stimulated cAMP accumulation in NCI-H716 enteroendocrine cells. Conclusions and Implications: Knowledge of signalling pathways activated by INSL5 at RXFP4 receptors is essential for understanding the biological roles of this novel gut hormone.

Original languageEnglish
Pages (from-to)1077-1089
Number of pages13
JournalBritish Journal of Pharmacology
Volume174
Issue number10
DOIs
Publication statusPublished - 1 May 2017

Cite this

@article{9fc09938f18549998c446fda4a57793a,
title = "Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor",
abstract = "Background and Purpose: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. Experimental Approach: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen{\circledR} proximity assays. Recruitment of Gαi/o proteins by RXFP4 receptors was determined by rescue of Pertussis toxin (PTX)-inhibited cAMP and ERK1/2 responses following transient transfection of PTX-insensitive Gαi/o C351I mutants. Cell proliferation was studied with bromodeoxyuridine. RXFP4 receptor interactions with β-arrestins, GPCR kinase 2 (GRK2), KRas and Rab5a was assessed with real-time BRET. Gene expression was investigated using real-time quantitative PCR. Insulin release was measured using HTRF and intracellular Ca2 + flux monitored in a Flexstation{\circledR} using Fluo-4-AM. Key Results: INSL5 inhibited forskolin-stimulated cAMP accumulation and increased phosphorylation of ERK1/2, p38MAPK, Akt Ser473, Akt Thr308 and S6 ribosomal protein. cAMP and ERK1/2 responses were abolished by PTX and rescued by mGαoA, mGαoB and mGαi2 and to a lesser extent mGαi1 and mGαi3. RXFP4 receptors interacted with GRK2 and β-arrestins, moved towards Rab5a and away from KRas, indicating internalisation following receptor activation. INSL5 inhibited glucose-stimulated insulin secretion and Ca2 + mobilisation in MIN6 insulinoma cells and forskolin-stimulated cAMP accumulation in NCI-H716 enteroendocrine cells. Conclusions and Implications: Knowledge of signalling pathways activated by INSL5 at RXFP4 receptors is essential for understanding the biological roles of this novel gut hormone.",
author = "Ang, {Sheng Y} and Hutchinson, {Dana S} and Nitin Patil and Evans, {Bronwyn A} and Bathgate, {Ross A D} and Halls, {Michelle L.} and Hossain, {Mohammed A.} and Summers, {Roger J} and Martina Kocan",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/bph.13522",
language = "English",
volume = "174",
pages = "1077--1089",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "10",

}

Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor. / Ang, Sheng Y; Hutchinson, Dana S; Patil, Nitin; Evans, Bronwyn A; Bathgate, Ross A D; Halls, Michelle L.; Hossain, Mohammed A.; Summers, Roger J; Kocan, Martina.

In: British Journal of Pharmacology, Vol. 174, No. 10, 01.05.2017, p. 1077-1089.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor

AU - Ang, Sheng Y

AU - Hutchinson, Dana S

AU - Patil, Nitin

AU - Evans, Bronwyn A

AU - Bathgate, Ross A D

AU - Halls, Michelle L.

AU - Hossain, Mohammed A.

AU - Summers, Roger J

AU - Kocan, Martina

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background and Purpose: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. Experimental Approach: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen® proximity assays. Recruitment of Gαi/o proteins by RXFP4 receptors was determined by rescue of Pertussis toxin (PTX)-inhibited cAMP and ERK1/2 responses following transient transfection of PTX-insensitive Gαi/o C351I mutants. Cell proliferation was studied with bromodeoxyuridine. RXFP4 receptor interactions with β-arrestins, GPCR kinase 2 (GRK2), KRas and Rab5a was assessed with real-time BRET. Gene expression was investigated using real-time quantitative PCR. Insulin release was measured using HTRF and intracellular Ca2 + flux monitored in a Flexstation® using Fluo-4-AM. Key Results: INSL5 inhibited forskolin-stimulated cAMP accumulation and increased phosphorylation of ERK1/2, p38MAPK, Akt Ser473, Akt Thr308 and S6 ribosomal protein. cAMP and ERK1/2 responses were abolished by PTX and rescued by mGαoA, mGαoB and mGαi2 and to a lesser extent mGαi1 and mGαi3. RXFP4 receptors interacted with GRK2 and β-arrestins, moved towards Rab5a and away from KRas, indicating internalisation following receptor activation. INSL5 inhibited glucose-stimulated insulin secretion and Ca2 + mobilisation in MIN6 insulinoma cells and forskolin-stimulated cAMP accumulation in NCI-H716 enteroendocrine cells. Conclusions and Implications: Knowledge of signalling pathways activated by INSL5 at RXFP4 receptors is essential for understanding the biological roles of this novel gut hormone.

AB - Background and Purpose: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. Experimental Approach: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen® proximity assays. Recruitment of Gαi/o proteins by RXFP4 receptors was determined by rescue of Pertussis toxin (PTX)-inhibited cAMP and ERK1/2 responses following transient transfection of PTX-insensitive Gαi/o C351I mutants. Cell proliferation was studied with bromodeoxyuridine. RXFP4 receptor interactions with β-arrestins, GPCR kinase 2 (GRK2), KRas and Rab5a was assessed with real-time BRET. Gene expression was investigated using real-time quantitative PCR. Insulin release was measured using HTRF and intracellular Ca2 + flux monitored in a Flexstation® using Fluo-4-AM. Key Results: INSL5 inhibited forskolin-stimulated cAMP accumulation and increased phosphorylation of ERK1/2, p38MAPK, Akt Ser473, Akt Thr308 and S6 ribosomal protein. cAMP and ERK1/2 responses were abolished by PTX and rescued by mGαoA, mGαoB and mGαi2 and to a lesser extent mGαi1 and mGαi3. RXFP4 receptors interacted with GRK2 and β-arrestins, moved towards Rab5a and away from KRas, indicating internalisation following receptor activation. INSL5 inhibited glucose-stimulated insulin secretion and Ca2 + mobilisation in MIN6 insulinoma cells and forskolin-stimulated cAMP accumulation in NCI-H716 enteroendocrine cells. Conclusions and Implications: Knowledge of signalling pathways activated by INSL5 at RXFP4 receptors is essential for understanding the biological roles of this novel gut hormone.

UR - http://www.scopus.com/inward/record.url?scp=84978221613&partnerID=8YFLogxK

U2 - 10.1111/bph.13522

DO - 10.1111/bph.13522

M3 - Article

VL - 174

SP - 1077

EP - 1089

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 10

ER -